Sean E Collins

1.7k total citations
30 papers, 738 citations indexed

About

Sean E Collins is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Sean E Collins has authored 30 papers receiving a total of 738 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Infectious Diseases, 20 papers in Virology and 7 papers in Emergency Medicine. Recurrent topics in Sean E Collins's work include HIV/AIDS drug development and treatment (22 papers), HIV Research and Treatment (20 papers) and HIV/AIDS Research and Interventions (13 papers). Sean E Collins is often cited by papers focused on HIV/AIDS drug development and treatment (22 papers), HIV Research and Treatment (20 papers) and HIV/AIDS Research and Interventions (13 papers). Sean E Collins collaborates with scholars based in United States, France and Haiti. Sean E Collins's co-authors include Hal Martin, Rima Acosta, Diana M. Brainard, Jean W. Pape, Daniel W. Fitzgerald, Xuelian Wei, Paul E. Sax, Oksana Ocheretina, Yazdan Yazdanpanah and Vincent Escuyer and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Sean E Collins

29 papers receiving 719 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sean E Collins United States	15	636	350	246	204	68	30	738
Isabel Cassetti Argentina	15	875 1.4×	517 1.5×	334 1.4×	258 1.3×	26 0.4×	48	1.1k
Arkaitz Imaz Spain	16	574 0.9×	390 1.1×	111 0.5×	221 1.1×	13 0.2×	81	744
Henry Sunpath United States	19	914 1.4×	630 1.8×	114 0.5×	245 1.2×	35 0.5×	47	1.0k
Guido E.L. van den Berk Netherlands	8	243 0.4×	110 0.3×	124 0.5×	303 1.5×	27 0.4×	13	550
Joseph J. Eron United States	16	978 1.5×	734 2.1×	297 1.2×	186 0.9×	14 0.2×	29	1.1k
Ndwapi Ndwapi United States	14	681 1.1×	485 1.4×	116 0.5×	215 1.1×	24 0.4×	17	753
Ruth Goodall United Kingdom	16	597 0.9×	370 1.1×	118 0.5×	242 1.2×	80 1.2×	47	893
JM Gatell Spain	13	593 0.9×	354 1.0×	255 1.0×	282 1.4×	39 0.6×	28	805
Maureen Wellington South Africa	15	884 1.4×	714 2.0×	67 0.3×	196 1.0×	21 0.3×	22	1.0k
Steven Y. Hong United States	14	527 0.8×	244 0.7×	73 0.3×	223 1.1×	29 0.4×	34	675

Countries citing papers authored by Sean E Collins

Since Specialization

Citations

This map shows the geographic impact of Sean E Collins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sean E Collins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sean E Collins more than expected).

Fields of papers citing papers by Sean E Collins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sean E Collins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sean E Collins. The network helps show where Sean E Collins may publish in the future.

Co-authorship network of co-authors of Sean E Collins

This figure shows the co-authorship network connecting the top 25 collaborators of Sean E Collins. A scholar is included among the top collaborators of Sean E Collins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sean E Collins. Sean E Collins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eron, Joseph J., Paul Cook, Megha Mehrotra, et al.. (2025). Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab. The Journal of Infectious Diseases. 231(6). 1440–1444. 1 indexed citations

Selzer, Lisa, Laurie A. VanderVeen, Ross Martin, et al.. (2024). Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People With HIV-1 Suppressed by Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 98(1). 64–71. 2 indexed citations

Eron, Joseph J., Susan J. Little, Gordon Crofoot, et al.. (2024). Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study. The Lancet HIV. 11(3). e146–e155. 24 indexed citations

Yao, Zhiwen, Patrice Sévère, Sean E Collins, et al.. (2021). Long‐term mortality after tuberculosis treatment among persons living with HIV in Haiti. Journal of the International AIDS Society. 24(7). 7 indexed citations

Orkin, Chloe, Faïza Ajana, Cissy Kityo, et al.. (2021). Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes. 88(4). 393–398. 5 indexed citations

Acosta, Rima, Madeleine Willkom, Kristen Andreatta, et al.. (2020). Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance. JAIDS Journal of Acquired Immune Deficiency Syndromes. 85(3). 363–371. 20 indexed citations

Hagins, Debbie, Princy Kumar, Michael S. Saag, et al.. (2020). 1046. Week 48 Outcomes from the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in African American Adults with HIV. Open Forum Infectious Diseases. 7(Supplement_1). S552–S553. 1 indexed citations

Trevaskis, James L., Christoph C Carter, Kirsten White, et al.. (2020). Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight. PLoS ONE. 15(2). e0229617–e0229617. 32 indexed citations

Eron, Joseph J., Aimee Wilkin, Moti Ramgopal, et al.. (2020). 1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis. Open Forum Infectious Diseases. 7(Supplement_1). S529–S530. 6 indexed citations

10.

Sax, Paul E., Jürgen K. Rockstroh, Anne F. Luetkemeyer, et al.. (2020). Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. Clinical Infectious Diseases. 73(2). e485–e493. 80 indexed citations

11.

Wohl, David A., Yazdan Yazdanpanah, Axel Baumgarten, et al.. (2019). Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The Lancet HIV. 6(6). e355–e363. 116 indexed citations

12.

Stellbrink, Hans‐Jürgen, José Ramón Arribas, Jeffrey L. Stephens, et al.. (2019). Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The Lancet HIV. 6(6). e364–e372. 99 indexed citations

13.

Sax, Paul E., Edwin DeJesus, Gordon Crofoot, et al.. (2018). Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide. AIDS. 32(12). 1723–1725. 7 indexed citations

14.

Sax, Paul E., Edwin DeJesus, Gordon Crofoot, et al.. (2017). A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination. Open Forum Infectious Diseases. 4(suppl_1). S426–S427. 1 indexed citations

15.

Ocheretina, Oksana, Li Shen, Vincent Escuyer, et al.. (2015). Whole Genome Sequencing Investigation of a Tuberculosis Outbreak in Port-au-Prince, Haiti Caused by a Strain with a “Low-Level” rpoB Mutation L511P – Insights into a Mechanism of Resistance Escalation. PLoS ONE. 10(6). e0129207–e0129207. 15 indexed citations

16.

Collins, Sean E, Philip Grant, & Robert W. Shafer. (2015). Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. Drugs. 76(1). 75–98. 17 indexed citations

17.

Ocheretina, Oksana, Vincent Escuyer, Sean E Collins, et al.. (2014). Correlation between Genotypic and Phenotypic Testing for Resistance to Rifampin in Mycobacterium tuberculosis Clinical Isolates in Haiti: Investigation of Cases with Discrepant Susceptibility Results. PLoS ONE. 9(3). e90569–e90569. 91 indexed citations

18.

Richardson, Eugene T, Sean E Collins, Tiffany H. Kung, et al.. (2014). Gender inequality and HIV transmission: a global analysis. Journal of the International AIDS Society. 17(1). 19035–19035. 63 indexed citations

19.

Collins, Sean E, et al.. (2014). Pharmacist’s Counselling Improves Patient Knowledge Regarding Warfarin, Irrespective of Health Literacy Level. SHILAP Revista de lepidopterología. 2(1). 114–123. 15 indexed citations

20.

Koenig, Serena P., Cynthia Riviere, Paul Leger, et al.. (2009). High Mortality among Patients with AIDS Who Received a Diagnosis of Tuberculosis in the First 3 Months of Antiretroviral Therapy. Clinical Infectious Diseases. 48(6). 829–831. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact